Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CLL1-CD33 cCART cell therapy / iCell Gene Therap
NCT03795779: CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies	Recruiting	1	20	RoW	CLL1-CD33 cCAR T cells	iCell Gene Therapeutics, The General Hospital of Western Theater Command, iCAR Bio Therapeutics Ltd., Peking University Shenzhen Hospital	Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Chronic Myeloid Leukemia	09/22	09/22